Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 328 participants.
Also called NCT04004793
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 328 participants
- Sponsor
- Registry
-
NCT04004793
-
- Other papers using this trial's data
- Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04004793. Randomized; triple masking; primary purpose treatment. Start 2020-06-12 (actual); primary completion 2023-01-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)
- Acronym
- READ
- Condition
- Type 2 Diabetes
- Intervention (Behavioral)
- Intensive lifestyle intervention
- Intervention (Drug)
- Dapagliflozin 10 MG Oral Tablet
- Intervention (Drug)
- Placebo Oral Tablet
- Lead sponsor
- Shanghai Zhongshan Hospital
Record details
- Record id
cardio:ct-nct04004793- Content hash
e512ac4c1f850121889dbd4d5531af46af5b6c7c8a22d5358320c750d95d7b12